1. Department of Medicine, Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany.
DZIF Partner Site (German Center for Infection Research), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany.
Sci Transl Med. 2020 May 6;12(542). doi: 10.1126/scitranslmed.aay9355.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only medical intervention that has led to an HIV cure. Whereas the HIV reservoir sharply decreases after allo-HSCT, the dynamics of the T cell reconstitution has not been comprehensively described. We analyzed the activation and differentiation of CD4 and CD8 T cells, and the breadth and quality of HIV- and CMV-specific CD8 T cell responses in 16 patients with HIV who underwent allo-HSCT (including five individuals who received cells from CCR5Δ32/Δ32 donors) to treat their underlying hematological malignancy and who remained on antiretroviral therapy (ART). We found that reconstitution of the T cell compartment after allo-HSCT was slow and heterogeneous with an initial expansion of activated CD4 T cells that preceded the expansion of CD8 T cells. Although HIV-specific CD8 T cells disappeared immediately after allo-HSCT, weak HIV-specific CD8 T cell responses were detectable several weeks after transplant and could still be detected at the time of full T cell chimerism, indicating that de novo priming, and hence antigen exposure, occurred during the time of T cell expansion. These HIV-specific T cells had limited functionality compared with CMV-specific CD8 T cells and persisted years after allo-HSCT. In conclusion, immune reconstitution was slow, heterogeneous, and incomplete and coincided with de novo detection of weak HIV-specific T cell responses. The initial short phase of high T cell activation, in which HIV antigens were present, may constitute a window of vulnerability for the reseeding of viral reservoirs, emphasizing the importance of maintaining ART directly after allo-HSCT.
异基因造血干细胞移植(allo-HSCT)是唯一导致 HIV 治愈的医学干预措施。虽然 allo-HSCT 后 HIV 储存库急剧减少,但 T 细胞重建的动力学尚未得到全面描述。我们分析了 16 例接受 allo-HSCT(包括 5 例接受 CCR5Δ32/Δ32 供体细胞的患者)以治疗其潜在血液恶性肿瘤且仍接受抗逆转录病毒治疗(ART)的 HIV 患者的 CD4 和 CD8 T 细胞的激活和分化,以及 HIV 和 CMV 特异性 CD8 T 细胞反应的广度和质量。我们发现 allo-HSCT 后 T 细胞区室的重建是缓慢且异质的,伴有激活的 CD4 T 细胞的初始扩张,随后是 CD8 T 细胞的扩张。尽管 allo-HSCT 后 HIV 特异性 CD8 T 细胞立即消失,但在移植后数周可检测到微弱的 HIV 特异性 CD8 T 细胞反应,并且在完全 T 细胞嵌合体时仍可检测到,表明在 T 细胞扩增期间发生了新的启动,从而暴露于抗原。与 CMV 特异性 CD8 T 细胞相比,这些 HIV 特异性 T 细胞的功能有限,并且在 allo-HSCT 后多年仍持续存在。总之,免疫重建缓慢、异质且不完全,同时伴有新出现的微弱 HIV 特异性 T 细胞反应的检测。高 T 细胞激活的初始短阶段,其中存在 HIV 抗原,可能构成病毒储存库重新播种的脆弱窗口,强调了 allo-HSCT 后直接维持 ART 的重要性。